D. Commenges, Estimation of dynamical model parameters taking into account 575 undetectable marker values, BMC Med. Res. Methodol, vol.6, p.38, 2006.

A. Perelson, Analysis of the hepatitis C viral kinetics during administration of 578 two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938, Antivir. Ther, vol.19, issue.220, pp.211-579, 2014.

C. Laouénan, J. Guedj, and F. Mentré, Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach, BMC Medical Research Methodology, vol.14, issue.10, pp.60-583, 2013.
DOI : 10.3851/IMP2428

J. Holmes, P. Desmond, and A. Thompson, Does IL28B genotyping still have a 584 role in the era of direct-acting antiviral therapy for chronic hepatitis C infection, p.585, 2012.

M. Cunningham and G. Foster, Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection, Therapeutic Advances in Gastroenterology, vol.5, issue.2, pp.139-151, 2012.
DOI : 10.1177/1756283X11426895

S. Chevaliez, C. Rodriguez, and J. Pawlotsky, New Virologic Tools for Management of Chronic Hepatitis B and C, Gastroenterology, vol.142, issue.6, pp.1303-1313, 2012.
DOI : 10.1053/j.gastro.2012.02.027
URL : https://hal.archives-ouvertes.fr/inserm-00699942

S. Dominguez, J. Ghosn, B. Cassard, G. Melica, I. Poizot-martin et al., Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV, Journal of Antimicrobial Chemotherapy, vol.67, issue.6, pp.1449-1452, 2012.
DOI : 10.1093/jac/dks045